Oncology Central

Pembrolizumab becomes the first and only immunotherapy to be recommended by NICE for urothelial carcinoma patients

NICE has issued final guidance recommending the use of the immunotherapy KEYTRUDA® (pembrolizumab) within the cancer drugs fund (CDF) as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines


Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.